An Evaluation of the Clinical Utility of Thrombelastography (TEG) in Guiding Low Molecular Weight Heparin (LMWH) and Antiplatelet Prophylaxis of Venous Thromboembolism (VTE) Following Trauma.

Trial Profile

An Evaluation of the Clinical Utility of Thrombelastography (TEG) in Guiding Low Molecular Weight Heparin (LMWH) and Antiplatelet Prophylaxis of Venous Thromboembolism (VTE) Following Trauma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2014

At a glance

  • Drugs Dalteparin sodium (Primary) ; Aspirin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms VTEPX
  • Most Recent Events

    • 24 Apr 2014 Number of drugs decreased from 4 to 2. In arm-2, 4 drugs were given previously (Dalteparin sodium/aspirin, dipyridamole/clopidogrel), but presently arm-2 consist of only 2 drugs (Dalteparin sodium/aspirin).
    • 16 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Apr 2011 Planned end date changed from 1 Aug 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top